

<b>FORM PTO-1449</b> <b>INFORMATION DISCLOSURE STATEMENT</b>					<b>SERIAL NO.</b> 10/529,922	
					<b>FILING DATE</b> March 30, 2005	
					<b>APPLICANT</b> BACUS et al.	
					<b>GROUP</b> 	
					<b>EXAMINER</b> 	
					<b>ATTORNEY DOCKET NO.</b> PU4995USw	

U.S. PATENT DOCUMENTS

Examiner Initials	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
JLH ↓	1.	2003/0124130	Brown			
	2.	2003/0152959	Mertz et al.			

Continue on page \_\_\_\_\_

FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Subclass	Translation Yes   No
gu ↓	3.	2005/011607	PCT		
	4.	2005/017493	PCT		
	5.	2005/121380	PCT		

Continue on page \_\_\_\_\_

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)


Gru	6.	XIA et al., Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways, Oncogene 21:6255-6263 (2002).

Continue on page \_\_\_\_\_

<b>EXAMINER</b> 	<b>DATE CONSIDERED</b> 9/19/07
---------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.



<b>FORM PTO-1449</b>				<b>SERIAL NO.</b>		10/529,922	
<b>INFORMATION DISCLOSURE STATEMENT</b>				<b>FILING DATE</b>		March 30, 2005	
				<b>APPLICANT</b>		BACUS et al.	
				<b>GROUP</b>			
				<b>EXAMINER</b>			
				<b>ATTORNEY DOCKET NO.</b>		PU4995USw	
<b>U.S. PATENT DOCUMENTS</b>							
<b>Examiner Initials</b>		<b>Patent Number</b>	<b>Issue Date</b>	<b>Name</b>	<b>Class</b>	<b>Subclass</b>	<b>Filing Date If Appropriate</b>
	1.	6,001,580	12/14/1999	Tani et al.			
Continue on page _____							
<b>FOREIGN PATENT DOCUMENTS</b>							
		<b>Document Number</b>	<b>Publication Date</b>	<b>Country</b>	<b>Class</b>	<b>Subclass</b>	<b>Translation Yes   No</b>
Continue on page _____							
<b>OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)</b>							
54	2.	ALBANELL et al., Pharmacodynamic Studies with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839, <i>Seminars in Oncology</i> 28(5), Suppl 16:56-66 (2001).					
	3.	ALBANELL et al., Activated Extracellular Signal-regulated Kinases: Association with Epidermal Growth Factor Receptor/Transforming Growth Factor $\alpha$ Expression in Head and Neck Squamous Carcinoma and Inhibition by Anti-Epidermal Growth Factor Receptor Treatments, <i>Cancer Research</i> 61:6500-6510 (2001).					
	4.	ANDERSON et al., ZD1839 (IRESSA), A Novel Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, Potently Inhibits the Growth of EGFR-Positive Cancer Cell Lines With or Without ERBB2 Overexpression, <i>Int. J. Cancer</i> 94:774-782 (2001).					
	5.	FILARDO et al., Estrogen-Induced Activation of Erk-1 and Erk-2 Requires the G Protein-Coupled Receptor Homolog, GPR30, and Occurs via Trans-Activation of the Epidermal Growth Factor Receptor through Release of HB-EGF, <i>Molecular Endocrinology</i> 14(10):1649-1660 (2000).					
	6.	GEE et al., Phosphorylation of Erk1/2 Mitogen-Activated Protein Kinase is Associated with Poor Response to Anti-Hormonal Therapy and Decreased Patient Survival in Clinical Breast Cancer, <i>Int. J. Cancer</i> 95:247-254 (2001).					
	7.	PAWELETZ et al., Reverse Phase Protein Microarrays which Capture Disease Progression Show Activation of Pro-survival Pathways at the Cancer Invasion Front, <i>Oncogene</i> 20:1981-1989 (2001).					
	8.	RUSNAK et al., The Effects of the Novel, Reversible Epidermal Growth Factor Receptor/ErbB-2 Tyrosine Kinase Inhibitor, GW2016, on the Growth of Human Normal and Tumor-derived Cell Lines <i>In Vitro</i> and <i>In Vivo</i> , <i>Molecular Cancer Therapeutics</i> 1:85-94 (2001).					
	9.	SOLORZANO et al., <i>In Vivo</i> Intracellular Signaling as a Marker of Antiangiogenic Activity, <i>Cancer Research</i> 61:7048-7051 (2001).					
Continue on page _____							
<b>EXAMINER</b>					<b>DATE CONSIDERED</b>		
					9/14/07		
<b>EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							